Significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio as prognostic predictors after liver transplantation

Table 1 The clinical parameters, n (%)

Characteristics (n = 155)	Patients	P value
Donor age, median (IQR)	68 (56-78)
Donor BMI, median (IQR)	24 (21-27)
ECD	48 (31)
Recipient age, median (IQR)	58.1 (54-65)
Recipient male gender
Female	28 (18.1)	0.0017
Male	127 (81.9)
Recipient BMI, median (IQR)	26 (22-29)
MELD at listing, median (IQR)	18 (11-26)
MELD at LT, median (IQR)	21.6 (15-32)
Main indication to LT		0.038
Alcohol	55 (35.5)
Hepatitis C virus disease	25 (16.1)
Hepatitis B virus disease	17 (11)
MAFLD	34 (22.6)
Cholestatic	8 (5.2)
Cryptogenic	4 (2.6)
Haemochromatosis	6 (3.9)
Acute liver failure	2 (1.3)
Autoimmune	1 (0.6)
HCC co-indication	86 (55.5)
Intra-operative RBC transfusions, median (IQR)	4 (0-12)
30-day Clavien-Dindo complications
I-IIIB	72 (46.5)	0.002
IV-V	7 (4.5)
30-day infection	39 (25.2)
30-day sepsis	6 (4)
30-day hemorrhage	6 (4)
Post-LT ICU stay, median (IQR)	7 (2-16)
Post-LT LOS, median (IQR)	18 (14.5-28)
Acute rejection diagnosis	12 (7.7)
30-day patient death	5 (3.2)
30-day graft loss	6 (3.9)

IQR: Interquartile range; BMI: Body mass index; ECD: Extended criteria donors; MELD: Model for end-stage liver disease; LT: Liver transplant; MAFLD: Metabolic associated liver disease; HCC: Hepatocellular carcinoma; RBC: Red blood cell; ICU: Intensive care unit; LOS: Length of stay.